Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 1/20 | 0.43 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3243855 | 0.84 | METAP1 (0.56) | METAP1NAMPTATRTDP2BRD9 | |
| SCHEMBL6868944 | 0.84 | METAP1 (0.56) | METAP1NAMPTATRTDP2BRD9 | |
| SCHEMBL30668778 | 0.84 | METAP1 (0.56) | METAP1NAMPTATRTDP2BRD9 | |
| SCHEMBL15266282 | 0.84 | METAP1 (0.56) | METAP1NAMPTATRTDP2BRD9 | |
| SCHEMBL12567761 | 0.83 | HPGD (0.44) | METAP1LMNAPOLBRAB9ABRD4 | |
| SCHEMBL393203 | 0.83 | METAP1 (0.55) | METAP1NAMPTATRTDP2BRD9 | |
| SCHEMBL21567565 | 0.83 | METAP1 (0.55) | METAP1NAMPTATRTDP2BRD9 | |
| SCHEMBL2363495 | 0.83 | METAP1 (0.55) | METAP1NAMPTATRTDP2BRD9 | |
| SCHEMBL1699207 | 0.83 | ATR (0.56) | METAP1ATRLMNAPOLBRAB9A | |
| SCHEMBL1580424 | 0.83 | METAP1 (0.55) | METAP1NAMPTATRTDP2BRD9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311813-B | Palladium-catalyzed meta-C-H functionalized universal ligands | 斯克利普斯研究院 | 2023-02-28 | — | — | CN | disclosed |
| US-10696635-B2 | Versatile ligand for palladium-catalyzed meta-C—H functionalizations of aromatic substrates | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190119212-A1 | A VERSATILE LIGAND FOR PALLADIUM-CATALYZED META-C-H FUNCTIONALIZATIONS | THE SCRIPPS RESEARCH INSTITUTE | 2019-04-25 | — | — | US | disclosed |
| WO-2017184589-A1 | A VERSATILE LIGAND FOR PALLADIUM-CATALYZED META-C-H FUNCTIONALIZATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-10-26 | — | — | WO | disclosed |
| EP-2086993-B1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2015-03-11 | — | — | EP | disclosed |
| US-8471063-B2 | Michael systems as transglutaminase inhibitors | ZEDIRA GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| EP-2086993-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | Zedira GmbH (DE) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008055488-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2008-05-15 | — | — | WO | disclosed |
| US-6514997-B2 | Block the activity of picornaviral 3C protease | AGOURON PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1252145-A1 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20010047006-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001040189-A1 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119212-A1 | A VERSATILE LIGAND FOR PALLADIUM-CATALYZED META-C-H FUNCTIONALIZATIONS | AHR, PAH, DOHH | METAP1 170/4885NAMPT 2121/4885ATR 3458/4885 |
| US-10696635-B2 | Versatile ligand for palladium-catalyzed meta-C—H functionalizations of aromatic substrates | PAH, AHR, DDC | METAP1 171/4885NAMPT 2688/4885ATR 2778/4885 |
| US-20010047006-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | RNASE1, SERPINB1, RNASEH1 | METAP1 147/4885NAMPT 2190/4885ATR 4771/4885 |
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | TGM2, TGM3, TGM1 | METAP1 116/4885NAMPT 1652/4885ATR 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.